The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
https://doi.org/10.14341/omet2016360-63
Abstract
Objectives: To assess the risk of pregnancy and fetal pathology in patients with prolactin-secreting tumors treated with cabergoline in the early stages of gestation.
Materials and methods: The study included 24 patients in the age from 24 to 38 years old with prolactin-secreting tumors, become pregnant during therapy with cabergoline (Dostinex). A retrospective analysis of the course and outcomes of 33 pregnancies based on available medical records and questioning of the patients data.
Results: Of the 33 pregnancies resulted in births 26 (78.8%), registered a spontaneous miscarriage at 7 weeks period (3%), six women required medical abortions due to the undeveloping pregnancy for a period of 4 to 7 weeks (18.2%). In 6% of cases (two pregnant) gestational diabetes mellitus (GDM) has been diagnosed. The average gestational age was 39.8 weeks (36–41 weeks). Preterm delivery occurred in 4 women, accounting for 15.3%. In 6% of cases (two pregnant) gestational diabetes mellitus (GDM) has been diagnosed. In total 27 children were born (in 1 case - twins), 26 (96.3%) of which at the time of birth – are healthy. The vast majority of pregnancies ended with the birth of a healthy child growth and development that did not differ from those of their peers in the general population, which corresponds to the data released by the majority of foreign researchers.
Conclusions: The study confirms the absence of direct adverse effects of cabergoline (Dostinex) on the course and outcome of pregnancies in women receiving the drug at therapeutic doses before pregnancy and during the first 8 weeks of gestation.
About the Authors
Larisa Dzeranova
Endocrinology Research Centre, Moscow, Russia
Russian Federation
MD, ScD
Russian Federation
MD, ScD
Daria Skuridina
The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia
Russian Federation
Russian Federation
Svetlana Vorotnicova
Endocrinology Research Centre, Moscow, Russia
Russian Federation
postgraduate student
Russian Federation
postgraduate student
Ekaterina Pigarova
Endocrinology Research Centre, Moscow, Russia
Russian Federation
PhD
Russian Federation
PhD
References
1. Клиническая нейроэндокринология. Под ред. Дедова И.И. 2011; 113—118. [Clinical neuroendocrinology. Ed. by Dedov II. 2011; 113—118. (In Russ.)].
2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: 10.1210/jc.2010-1692.
3. Colao A, Lombardi G, Annunziato L. Сabergoline. Expert Opin Pharmacother. 2000;1(3):555—574.
4. Быканова Н.С., Пигарова Е.А. Гиперпролактинемия и беременность: основные достижения и нерешенные вопросы. // Вестник репродуктивного здоровья. – 2011. – T. 1. – C. 16—21. [Bykanova NA, Pigarova EA. Hyperprolactinemia and pregnancy: main achievements and outstanding issues. Bulletin of Reproductive Health. 2011;1:16—21 (In Russ.)].
5. Sundström E, Kölare S, Souverbie F, et al. Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res. Dev. Brain Res. 1993; 75(1): 1–12.
6. Herlenius Е, Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp. Neurol. 2004;190(Suppl 1):8–21.
7. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea Cabergoline. Comparative Study Group. New Engl. J. Med. 1994;331:942–944.
8. Colao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008;68(1):66-71. doi: 10.1111/j.1365-2265.2007.03000.x.
9. Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf). 2010:no-no. doi: 10.1111/j.1365-2265.2010.03808.x.
10. Ono M, Miki N, Amano K, et al. Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas. J Clin Endocrinol Metab. 2010;95(6):2672-2679. doi: 10.1210/jc.2009-2605.
11. Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol. 2002;16(6):791—793.
12. Bronstein MD, Paraiba DB, Jallad RS. Management of pituitary tumors in pregnancy. Nature Reviews Endocrinology. 2011;7(5):301-310. doi: 10.1038/nrendo.2011.38.
13. Auriemma RS, Perone Y, Di Sarno A, et al. Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. J Clin Endocrinol Metab. 2013;98(1):372-379. doi: 10.1210/jc.2012-3039.
14. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. doi: 10.1210/jcem.84.7.5810.
Review
For citations:
Dzeranova L., Skuridina D., Vorotnicova S., Pigarova E. The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline. Obesity and metabolism. 2016;13(3):60-63. (In Russ.) https://doi.org/10.14341/omet2016360-63
Views:
1181
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
